Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) Research & Development (2020 - 2025)

BioAtla (BCAB) has 6 years of Research & Development data on record, last reported at $9.5 million in Q3 2025.

  • For Q3 2025, Research & Development fell 41.82% year-over-year to $9.5 million; the TTM value through Sep 2025 reached $47.2 million, down 36.28%, while the annual FY2024 figure was $63.1 million, 39.17% down from the prior year.
  • Research & Development reached $9.5 million in Q3 2025 per BCAB's latest filing, down from $13.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $31.0 million in Q2 2023 and bottomed at $9.5 million in Q3 2025.
  • Average Research & Development over 5 years is $17.9 million, with a median of $16.6 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 527.51% in 2021, then plummeted 48.62% in 2024.
  • A 5-year view of Research & Development shows it stood at $16.4 million in 2021, then surged by 32.99% to $21.9 million in 2022, then rose by 3.66% to $22.7 million in 2023, then crashed by 48.62% to $11.6 million in 2024, then fell by 18.12% to $9.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $9.5 million in Q3 2025, $13.7 million in Q2 2025, and $12.4 million in Q1 2025.